Hilsenbeck SG - Search Results

1

A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.

Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT. Zhang X, et al. Among authors: hilsenbeck sg. Cancer Res. 2013 Aug 1;73(15):4885-97. doi: 10.1158/0008-5472.CAN-12-4081. Epub 2013 Jun 4. Cancer Res. 2013. PMID: 23737486 Free PMC article.

2

Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors.

Hundley JE, Koester SK, Troyer DA, Hilsenbeck SG, Barrington RE, Windle JJ. Hundley JE, et al. Among authors: hilsenbeck sg. Cancer Res. 1997 Feb 15;57(4):600-3. Cancer Res. 1997. PMID: 9044833

3

Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.

Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH. Clark GM, et al. Among authors: hilsenbeck sg. Cancer Res. 1997 Dec 15;57(24):5505-8. Cancer Res. 1997. PMID: 9407959

4

Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.

Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Brown RW, et al. Among authors: hilsenbeck sg. Clin Cancer Res. 1996 Mar;2(3):585-92. Clin Cancer Res. 1996. PMID: 9816207

5

Time-dependence of hazard ratios for prognostic factors in primary breast cancer.

Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Hilsenbeck SG, et al. Breast Cancer Res Treat. 1998;52(1-3):227-37. doi: 10.1023/a:1006133418245. Breast Cancer Res Treat. 1998. PMID: 10066085

6

Statistical analysis of array expression data as applied to the problem of tamoxifen resistance.

Hilsenbeck SG, Friedrichs WE, Schiff R, O'Connell P, Hansen RK, Osborne CK, Fuqua SA. Hilsenbeck SG, et al. J Natl Cancer Inst. 1999 Mar 3;91(5):453-9. doi: 10.1093/jnci/91.5.453. J Natl Cancer Inst. 1999. PMID: 10070945

7

Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.

Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S. Britten CD, et al. Among authors: hilsenbeck sg. Cancer Res. 1999 Mar 1;59(5):1049-53. Cancer Res. 1999. PMID: 10070962

8

A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.

Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DC. Fuqua SA, et al. Cancer Res. 2000 Aug 1;60(15):4026-9. Cancer Res. 2000. PMID: 10945602

9

Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.

Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Schiff R, et al. Among authors: hilsenbeck sg. J Natl Cancer Inst. 2000 Dec 6;92(23):1926-34. doi: 10.1093/jnci/92.23.1926. J Natl Cancer Inst. 2000. PMID: 11106684

10

Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.

Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GC. Chang J, et al. Among authors: hilsenbeck sg. Clin Cancer Res. 2001 Jun;7(6):1739-42. Clin Cancer Res. 2001. PMID: 11410514

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

366 results

Search Page